stockportfolio.pro
A vs BIIB: Which Stock Is the Better Buy?
Agilent Technologies, Inc. and Biogen Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — A vs BIIB, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Agilent Technologies, Inc. (A) | Biogen Inc. (BIIB) | |
|---|---|---|
| Market cap | $36.9B | $31.9B |
| Revenue (latest FY) | $6.95B | $9.89B |
| Net income (latest FY) | $1.30B | $1.29B |
| Revenue growth (5y CAGR) | 5.4% | -6.0% |
| Net margin | 18.8% | 13.1% |
| Return on equity | 19.3% | 7.1% |
| P/E ratio | 26.2 | 23.3 |
| Dividend yield | 0.8% | — |
| Profitable years (of last 10) | 10 | 10 |
| Positive free cash flow | Yes | Yes |
See the full A vs BIIB breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open A's full financials → Open BIIB's full financials →Frequently asked questions
Which is bigger, A or BIIB?
Agilent Technologies, Inc. is larger by market capitalization — $36.9B versus $31.9B.
Which grows faster, A or BIIB?
Over the last five fiscal years, Agilent Technologies, Inc. grew revenue faster — 5.4%/yr versus -6.0%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
A fundamentals → · BIIB fundamentals → · All 1,500+ companies → · Free screener →